Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Zacks04-18

Eli Lilly and Company LLY announced that its pipeline candidate, tirzepatide, met all primary and key secondary endpoints in two phase III studies evaluating it in adults with obstructive sleep apnea ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428134195?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","is_english":true,"pubTime":"2024-04-18 20:51","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2428134195","market":"us","top_or_hot":-1,"title":"Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies","media":"Zacks","content":"<div>\n<p>Eli Lilly and Company LLY announced that its pipeline candidate, tirzepatide, met all primary and key secondary endpoints in two phase III studies evaluating it in adults with obstructive sleep apnea ...</p>\n\n<a href=\"https://finance.yahoo.com/news/eli-lillys-lly-tirzepatide-meets-125100908.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 20:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/eli-lillys-lly-tirzepatide-meets-125100908.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly and Company LLY announced that its pipeline candidate, tirzepatide, met all primary and key secondary endpoints in two phase III studies evaluating it in adults with obstructive sleep apnea ...</p>\n\n<a href=\"https://finance.yahoo.com/news/eli-lillys-lly-tirzepatide-meets-125100908.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443382.USD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","start_time":0,"source_url":"https://finance.yahoo.com/news/eli-lillys-lly-tirzepatide-meets-125100908.html","article_id":"2428134195","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428134195","pubTimestamp":1713444660,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Eli Lilly and Company LLY announced that its pipeline candidate, tirzepatide, met all primary and key secondary endpoints in two phase III studies evaluating it in adults with obstructive sleep apnea  and obesity.OSA is a common sleep-related breathing disorder that causes repeated interruptions in breathing during sleep. This can lead to decreased oxygen levels in the blood, causing strain on the cardiovascular system and other organs over time. It can lead to complications like hypertension, coronary heart disease, stroke, heart failure, atrial fibrillation and type II diabetes.The first study evaluated tirzepatidein OSA patients who used breathing devices called positive airway pressure  for 52 weeks. These patients had 27.4 fewer sleep apnea events per hour on treatment with tirzepatide, compared to 4.8 event reductions for the placebo group.This means a mean AHI reduction of 55.0%. Eli Lilly’s stock has risen 101.7% in the past year compared with an increase of 13.8% for the indus","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LLY":"礼来","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4534":"瑞士信贷持仓","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4566":"资本集团","BK4007":"制药","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4082":"医疗保健设备","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","VKTX":"Viking Therapeutics, Inc.","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","AMGN":"安进","BK4097":"系统软件","AHI":"ADVANCED HEALTH INTELLIGENCE LTD SPON ADS EACH REP 7 ORD SHS","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC"},"translate_title":"Eli Lilly（LLY）替泽帕肽在睡眠呼吸暂停研究中达到目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"VKTX":1,"OSA":1,"LLY":1,"AHI":1,"NVO":0.9},"content_text":"Eli Lilly and Company LLY announced that its pipeline candidate, tirzepatide, met all primary and key secondary endpoints in two phase III studies evaluating it in adults with obstructive sleep apnea (OSA) and obesity.\nOSA is a common sleep-related breathing disorder that causes repeated interruptions in breathing during sleep. This can lead to decreased oxygen levels in the blood, causing strain on the cardiovascular system and other organs over time. It can lead to complications like hypertension, coronary heart disease, stroke, heart failure, atrial fibrillation and type II diabetes.\nThe SURMOUNT-OSA studies met the primary endpoints by showing that tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo. AHI measures the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the severity of OSA. Data from the SURMOUNT-OSA studies showed that treatment with tirzepatide resulted in a mean AHI reduction of up to 63%. This means tirzepatide has the potential to significantly improve the severity of OSA.\nThe first study evaluated tirzepatide in OSA patients who used breathing devices called positive airway pressure (PAP) for 52 weeks. These patients had 27.4 fewer sleep apnea events per hour on treatment with tirzepatide, compared to 4.8 event reductions for the placebo group. This means a mean AHI reduction of 55.0%\nPatients who were on PAP therapy had 30.4 fewer events every hour compared to 6.0 events per hour for placebo. This means a mean AHI reduction of 62.8%. The weight loss observed across the two studies was nearly 20% at 52 weeks.\nEli Lilly’s stock has risen 101.7% in the past year compared with an increase of 13.8% for the industry.\nImage Source: Zacks Investment Research\nBased on data from these studies, Lilly plans to file regulatory application to the FDA and other regulatory bodies by mid-2024.\nTirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), is marketed by the name of Mounjaro for type II diabetes and as Zepbound for obesity by Lilly.\nZepbound was approved in November 2023 and launched in December. Mounjaro was approved in May 2022 for treating type II diabetes and generated impressive sales of $3.86 billion in 2023. Zepbound generated sales of $175.8 million in 2023.\nThe addition of OSA to tirzepatide’s label should significantly boost revenues as, at present, there are no drugs approved for treating OSA.\nThe GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks. GLP-1 drugs are presently approved for treating type II diabetes and obesity. Lilly and Novo Nordisk are also evaluating their GLP-1 drugs for obesity-related diseases.\nThe GLP-1 segment is particularly attracting a lot of interest for the obesity indication. Other GLP-1 drugs that the FDA has approved are Novo Nordisk’s NVO semaglutide medicines, Ozempic and Rybelsus, for type II diabetes and Wegovy for obesity.\nDespite supply challenges, Wegovy is seeing strong prescription trends and is generating impressive revenues and profits for Novo Nordisk. Wegovy was approved by the FDA for lowering the risk of serious heart problems in obese/overweight adults in March.\nViking Therapeutics VKTX also has a dual GLP-1/GIP receptor agonist called VK2735 in its pipeline. VK2735 is subcutaneously injected once weekly. Another key pipeline candidate is amycretin, a GLP-1 and amylin co-agonist, being developed as an oral pill for obesity. Viking Therapeutics’ amycretin showed faster weight loss than Novo Nordisk’s Wegovy in a phase I study. Viking Therapeutics also has an oral formulation of VK2735 in phase I development. Data from the phase I study, released in March, showed the oral tablet’s promising early weight loss and tolerability profile.\nAmgen AMGN also has an interesting GLP-1 receptor (GLP-1R) candidate in its pipeline called maridebart cafraglutide, which is being developed in phase II for obesity. Maridebart cafraglutide is an antibody-peptide conjugate that has a dual mechanism of action. It activates GLP-1R and inhibits the GIP receptor.\nAmgen has another small-molecule obesity candidate in the pipeline called AMG-786, which is in phase I development. AMG 786 is not an incretin-based therapy and has a different target than maridebart cafraglutide.\nEli Lilly currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\n\nEli Lilly and Company Price and Consensus\n\nEli Lilly and Company price-consensus-chart | Eli Lilly and Company Quote\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nAmgen Inc. (AMGN) : Free Stock Analysis Report\nViking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428134195"}